CN110590768A - Heterocyclic compounds, compositions thereof and their use as anti-influenza virus agents - Google Patents
Heterocyclic compounds, compositions thereof and their use as anti-influenza virus agents Download PDFInfo
- Publication number
- CN110590768A CN110590768A CN201810605064.2A CN201810605064A CN110590768A CN 110590768 A CN110590768 A CN 110590768A CN 201810605064 A CN201810605064 A CN 201810605064A CN 110590768 A CN110590768 A CN 110590768A
- Authority
- CN
- China
- Prior art keywords
- formula
- substituted
- alkyl
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title claims abstract description 30
- 206010022000 influenza Diseases 0.000 title claims description 33
- 241000700605 Viruses Species 0.000 title abstract description 18
- 239000000203 mixture Substances 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 239000003112 inhibitor Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- -1 hydrocarbyl carbonyl oxygen Chemical compound 0.000 claims description 70
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 239000013078 crystal Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 239000002911 sialidase inhibitor Substances 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 239000000460 chlorine Substances 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 claims description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- 125000006425 chlorocyclopropyl group Chemical group 0.000 claims description 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 2
- 125000006419 fluorocyclopropyl group Chemical group 0.000 claims description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 208000037798 influenza B Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 241000712431 Influenza A virus Species 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000013518 transcription Methods 0.000 abstract description 4
- 230000035897 transcription Effects 0.000 abstract description 4
- 229940123066 Polymerase inhibitor Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 101710102873 Polymerase basic protein 2 Proteins 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PNZXSNMCWRRBPH-JJIXEQETSA-N CC1=C(C(=NC(=N1)C2=CNC3=C2C=C(C=N3)F)N[C@@H]4[C@H](C5CCC4C=C5)C(=O)O)F Chemical compound CC1=C(C(=NC(=N1)C2=CNC3=C2C=C(C=N3)F)N[C@@H]4[C@H](C5CCC4C=C5)C(=O)O)F PNZXSNMCWRRBPH-JJIXEQETSA-N 0.000 description 6
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 5
- 108010006232 Neuraminidase Proteins 0.000 description 5
- 102000005348 Neuraminidase Human genes 0.000 description 5
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- RZQRFJYKWMUYLB-UHFFFAOYSA-N bicyclo[2.2.2]oct-2-ene-5-carboxylic acid Chemical compound C1CC2C(C(=O)O)CC1C=C2 RZQRFJYKWMUYLB-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229940123734 Endonuclease inhibitor Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- JGPXDNKSIXAZEQ-SBBZOCNPSA-N (2s,3s)-3-[[5-fluoro-2-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid Chemical compound C1=C(F)C=C2C(C=3N=C(C(=CN=3)F)N[C@H]3C4CCC(CC4)[C@@H]3C(=O)O)=CNC2=N1 JGPXDNKSIXAZEQ-SBBZOCNPSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- OFLRAEXXDACTLJ-UHFFFAOYSA-N FC=1C=C2C(=NC1)N(C=C2B2OC(C(O2)(C)C)(C)C)S(=O)(=O)CC2=CC=CC=C2 Chemical compound FC=1C=C2C(=NC1)N(C=C2B2OC(C(O2)(C)C)(C)C)S(=O)(=O)CC2=CC=CC=C2 OFLRAEXXDACTLJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 101150053185 P450 gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012200 cell viability kit Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 1
- DKVRNHPCAOHRSI-KQYNXXCUSA-N 7-methyl-GTP Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O DKVRNHPCAOHRSI-KQYNXXCUSA-N 0.000 description 1
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101100028758 Influenza A virus (strain A/Swine/Wisconsin/1/1967 H1N1) PB1-F2 gene Proteins 0.000 description 1
- 241001661732 Isavirus Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102220617446 Leucine-rich repeat-containing protein 34_H10N_mutation Human genes 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101150103639 PB1 gene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 240000001068 Thogoto virus Species 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- VUYVXCJTTQJVKJ-UHFFFAOYSA-L palladium(2+);tricyclohexylphosphane;dichloride Chemical compound Cl[Pd]Cl.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 VUYVXCJTTQJVKJ-UHFFFAOYSA-L 0.000 description 1
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- IBIRZFNPWYRWOG-UHFFFAOYSA-N phosphane;phosphoric acid Chemical compound P.OP(O)(O)=O IBIRZFNPWYRWOG-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229950004058 pimodivir Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- ZRLVQFQTCMUIRM-UHFFFAOYSA-N potassium;2-methylbutan-2-olate Chemical compound [K+].CCC(C)(C)[O-] ZRLVQFQTCMUIRM-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a heterocyclic compound shown as a formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof and application thereof in preparing a medicament for treating or preventing influenza virus. As a novel virus polymerase inhibitor, the compounds can inhibit the transcription and synthesis of influenza A virus RNA, and compared with the existing virus polymerase inhibitors, the compounds have the advantages of remarkably better activity, better water solubility and simpler structure.
Description
Technical Field
The invention belongs to the field of medicinal chemistry, and particularly relates to a heterocyclic compound, a heterocyclic compound salt, a preparation method of the heterocyclic compound and an application of the heterocyclic compound salt as a medicament for treating and preventing influenza viruses.
Background
Influenza is a contagious disease that can be fatal, with high morbidity and mortality. 5-20% of people are infected with influenza virus every year, and other complications such as respiration or heart are caused, hundreds of thousands of people die each year worldwide, millions of people may die when influenza is pandemic, and tens of millions of people die after a major outbreak of influenza in the 20 th century. These pandemic influenza are caused by the mutation of influenza virus in animals and the transmission of the influenza virus from animal species to humans.
Influenza viruses belong to the orthomyxoviridae (orthomyxoviridae) family of antisense RNA viruses, including 5 species: type A viruses, type B viruses, type C viruses, Isavirus, and Thogoto viruses. Type a virus is a virus that is transmitted from birds to humans, has a high pathogenic rate, and is prevalent in large numbers with serious consequences. Different influenza viruses are classified according to the different serotypes of influenza a. For example, H1N1 caused spanish influenza in 1918, H2N2 caused asian influenza in 1957, H3N2 caused hong kong influenza in 1968, and H5N1 was the type of influenza between 2007 and 2008. Other examples include H1N2, H7N7, H9N2, H7N2, H7N3, and H10N 7.
The size of the influenza A virus particle is 80-120 nm. Its genome is not a single fragment of nucleic acid, but 8 fragments of antisense RNA. The 8 genomes of influenza a encode 11 proteins: hemagglutinin (HA), Neuraminidase (NA), Nucleoprotein (NP), M1, M2, NS1, NS2, PA, PB1, PB1-F2 and PB 2. HA and NA are macromolecular proteins outside the viral particle. HA is a lectin that mediates binding of the virus to target cells and entry of the viral genome into target cells, and NA is involved in the release of progeny viruses, so these proteins can all be targeted proteins for the development of influenza inhibitors.
The method of treating influenza is a vaccine or an antiviral drug. Since the vaccine is a main strain in the year every season, it is weak to infect patients other than the main strain or the elderly. In addition, influenza viruses mutate very quickly and vaccines need to be updated every year. If influenza is pandemic, it is a great challenge to be able to produce enough vaccines or to develop the right vaccine.
The standard antiviral drugs today are neuraminidase inhibitors, such as Oseltamivir (Oseltamivir) and Zanamivir (Zanamivir). These drugs can be used to treat influenza a and influenza B infected patients, but neuraminidase inhibitors must be treated within 48 hours of infection and may not be clinically effective in critically ill patients. In addition, influenza virus is highly mutated, and it has been reported that influenza H5N1 has resistance to neuraminidase inhibitors. The anti-influenza drugs have the function of preventing virus from spreading among human cells, and the drugs have no effect of preventing virus proliferation. Therefore, there is a need to develop new mechanisms and anti-influenza drugs with high efficacy, low toxicity and high mutation threshold to meet the needs of clinical and potential influenza outbreaks.
The polymerase of influenza viruses comprises three subunits: PB1, PB2 and PA, these three subunits being responsible for the replication and transcription of 8 RNA fragments. These three subunits are all targets for drug development. In the synthesis of viral mRNA, viral polymerase utilizes the host pre-mRNA as a primer for transcription by the "cap-snatchinging" mechanism, and the region of this mechanism is contained in the PB2 subunit for binding m7GTP of the m-RNA precursor. The PB2 inhibitor aiming at the region is an anti-influenza virus compound with a brand-new mechanism, and has great clinical application value.
The existing PB2 inhibitor is effective for influenza A virus, and can effectively inhibit known clinical serotype viruses, such as H1N1, H5N1 and the like. The PB2 inhibitor can effectively inhibit the transcription and synthesis of virus RNA, while the neuraminidase inhibitor has no effect on the synthesis of RNA. In addition, the neuraminidase inhibitor is effective for people with low virus infection, and the PB2 inhibitor has a protection effect on all MIOs, which indicates that the PB2 inhibitor has a good protection effect on severe patients. Unlike neuraminidase inhibitors which are only effective within 48 hours, PB2 inhibitors are still effective at 120 hours. Particularly, the combined medication of the PB2 inhibitor and the neuraminidase inhibitor greatly improves the clinical effect and prolongs the treatment time after the infection of the virus. The PB2 inhibitor and the PA endonuclease inhibitor are combined, and the animal model shows that the curative effect is better than that of a single medicament. In the future, the PB2 inhibitor, neuraminidase, PA endonuclease inhibitor and the like are combined, so that the rehabilitation of patients can be accelerated, and the survival rate of clinical patients can be improved.
Although some PB2 inhibitors have been reported in the prior art, the structures of the inhibitors are complex, the water solubility is poor, and the activity needs to be further improved. The development of novel PB2 inhibitors, either as replacements for or in combination with existing neuraminidase inhibitors and other anti-influenza drugs, is a clinically urgent need.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a novel heterocyclic compound which is a novel PB2 inhibitor, has remarkably stronger in-vitro activity for inhibiting influenza viruses and has more excellent pharmacokinetic properties.
In order to solve the technical problems, the invention adopts the following technical scheme:
the invention describes a heterocyclic compound shown in a formula (I) or an isomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof. In some embodiments of the invention described herein, isomers and other chemically protected forms having the structure represented by formula (I) are also provided, for example prodrug forms, esters and other prodrugs that include chemical hydrolysis or biodegradation to the acid. The heterocyclic compound provided by the invention has a structure shown in a formula (I),
wherein the content of the first and second substances,
R1selected from F or Cl;
R2the compound is selected from C1-C8 alkyl, C3-C6 cycloalkyl, substituted C1-C8 alkyl and substituted C3-C6 cycloalkyl, wherein the substituent of the substituted alkyl and the substituted cycloalkyl is one or more independently selected from fluorine, chlorine, C1-C8 alkyl and C1-C8 alkoxy;
R3selected from hydrogen, hydrocarbyl carbonyl oxygen of C1-C8, hydrocarbyl of C1-C4, hydrocarbyl oxygen carbonyl oxygen of C1-C8, hydrocarbyl-of C1-C4;
z is selected from N or CH.
According to a preferred aspect of the present invention, in the formula (I), R2Is selected from C1-C8 alkyl, C3-C6 cycloalkyl, substituted C1-C8 alkyl and substituted C3-C6 cycloalkyl, wherein the substituent groups in the substituted alkyl and the substituted cycloalkyl are independently one or more selected from fluorine, chlorine, C1-C8 alkyl and C1-C8 alkoxy. More preferably, in formula (I), R2Is selected from C1-C6 alkyl, C3-C6 cycloalkyl, substituted C1-C6 alkyl and substituted C3-C6 cycloalkyl, wherein the substituent groups in the substituted alkyl and the substituted cycloalkyl are independently one or more selected from fluorine, chlorine, C1-C3 alkyl and C1-C3 alkoxy.
According to some particularly preferred embodiments of the invention, in formula (I), R2Selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, fluoromethyl, fluoroethyl, fluoro-n-propyl, fluoro-isopropyl, fluoro-cyclopropyl, fluoro-cyclobutyl, fluoro-cyclopentyl, fluoro-cyclohexyl, chloromethyl, chloroethyl, chloro-n-propyl, chloro-isopropyl, chloro-cyclopropyl, chloro-cyclobutyl, chloro-cyclopentyl, chloro-cyclohexyl, methoxy-substituted methyl, methoxy-substituted ethyl, methoxy-substituted cyclopropyl, methoxy-substituted cyclobutyl, ethoxy-substituted methyl, ethoxy-substituted ethyl, ethoxy-substituted cyclopropyl, ethoxy-substituted cyclobutyl.
According to the invention, when the other groups constituting the compound are the same, for example, R as defined above2Replacement of a group with other possible groups, such as a thiophene ring or the like that forms an annulated structure with a pyrimidine ring, will result in a significant decrease in the water solubility of the compound, unstable metabolism, and in many cases a decrease in the activity of the compound.
According to still another preferred aspect of the present invention, in the formula (I), R3Selected from hydrogen, alkyl carbonyl oxygen of C1-C8, alkyl of C1-C4 and alkoxy carbonyl oxygen of C1-C8, and alkyl of C1-C4. More preferably, in formula (I), R3Selected from hydrogen, alkyl carbonyl oxygen of C1-C4, alkyl of C1-C2 and alkoxy carbonyl oxygen of C1-C4, and alkyl of C1-C2.
According to some particularly preferred embodiments of the invention, R3Selected from the group consisting of hydrogen, methylcarbonyloxymethyl-, methylcarbonyloxy 1-ethyl-, ethylcarbonyloxymethyl-, isopropylcarbonyloxymethyl-, tert-butylcarbonyloxymethyl-, methoxycarbonyloxymethyl-, methoxycarbonyloxy 1-ethyl-, ethoxycarbonyloxymethyl-, isopropoxycarbonyloxymethyl-, n-butyloxycarbonyloxymethyl-, isopropyloxycarbonyloxy 1-ethyl-。
In some embodiments according to the invention, R in formula (I)1Is Cl; r2Selected from methyl or cyclopropyl; r3Selected from alkyl carbonyl oxygen of H, C1-C8, alkyl of C1-C4, alkoxy carbonyl oxygen of C1-C8, and alkyl of C1-C4; z is selected from N or CH.
In still other embodiments according to the present invention, R in formula (I)1Is F; r2Selected from methyl or cyclopropyl; r3Selected from alkyl carbonyl oxygen of H, C1-C8, alkyl of C1-C4, alkoxy carbonyl oxygen of C1-C8, and alkyl of C1-C4; z is selected from N or CH.
In still other embodiments according to the invention, R in formula (I)1Is F; r2Is methyl; r3Is H; z is selected from CH or N.
In still other embodiments according to the present invention, R in formula (I)1Is F; r2Is cyclopropyl; r3Is H; z is selected from CH or N.
According to a preferred aspect of the present invention, in formula (I), Z is N.
According to the present invention, typical heterocyclic compounds represented by the general formula (I) are those represented by the following formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10), formula (I-11), formula (I-12), formula (I-13), formula (I-14), formula (I-15), formula (I-16), formula (I-17), formula (I-18), formula (I-19), formula (I-20), formula (I-21), formula (I-22), formula (I-23), formula (I-24), formula (I-25), formula (I-26), A compound represented by the formula (I-27), the formula (I-28), the formula (I-29), the formula (I-30), the formula (I-31), the formula (I-32), the formula (I-33), the formula (I-34), the formula (I-35), the formula (I-36), the formula (I-37), the formula (I-38), the formula (I-39) or the formula (I-40).
The present invention also provides a process for producing the heterocyclic compound represented by the general formula (I) of the present invention, which comprises:
(1) the compound A and the compound B are subjected to coupling reaction in the presence of a transition metal catalyst to obtain a compound C, and R related in the compound A, B, C1、R2、R3And Z is as defined above, P in compound A, C represents an amino protecting group; .
(2) Subjecting the compound C to basic hydrolysis and removal of the amino-protecting group to give a heterocyclic compound represented by the formula (I).
In the step (1), the transition metal catalyst may specifically be, for example, a palladium catalyst. A classical palladium catalyst is Pd (PPh)3)4(Ph＝phenyl),Pd(PPh3)2Cl2,Pd(dppf)2Cl2(dppf＝1,1’-Bis(diphenylphosphino)-ferrocene),Pd(acac)2(acac＝acetylacetonate),PdCl2(PCy3)2(PCy＝cyclohexyl),Pd2(dba)3(dba ═ dibenzylideneacetone), etc., these palladium catalysts are preferably used in combination with a phosphorus reagent for the coupling reaction.
The above-mentioned amino protecting group may be those known in the art, and is not particularly limited, and specifically, for example, p-toluenesulfonyl, 2- (trimethylsilyl) ethoxymethyl, tetrahydropyranyl or trityl, etc.
According to some embodiments of the invention, where formula A, C, (I) is where Z is CH and P is P-toluenesulfonyl, an exemplary implementation of step (2) is as follows: alkaline hydrolysis is carried out in the presence of inorganic base, and p-toluenesulfonyl and ethyl ester are sequentially removed to obtain the target product.
According to other embodiments of the present invention, in formula A, C, (I) where Z is N and P is tetrahydropyranyl or trityl, one exemplary implementation of step (2) is as follows: tetrahydropyranyl or trityl groups were removed with trifluoroacetic acid (TFA) and then basic hydrolysis was performed in the presence of an inorganic base.
The inorganic base is not particularly limited, and examples thereof include lithium hydroxide, sodium hydroxide, potassium hydroxide, and the like.
The invention also provides a prodrug of anti-influenza, which has a structure shown in a formula (II),
wherein R is1、R2Z is as defined above, R4Is selected from alkyl carbonyl-of C1-C8 or alkoxy carbonyl-of C1-C8. The prodrug design improves the physicochemical properties of the compound, enhances absorption, increases the bioavailability of the compound, and reduces the possible clinical dose. Prodrugs may in particular be, for example, the following compounds:
the heterocyclic compound and the salt thereof have strong activity of inhibiting influenza viruses, are about 4-10 times higher than the activity of the similar compound clinically at present, have excellent pharmacokinetic characteristics and have strong drug forming property. The introduction of hydrophobic substituent groups such as methyl and cyclopropyl can effectively enhance the interaction with a hydrophobic cavity of a PB2 subunit, and the activity of the compound is improved; meanwhile, the pyrimidine ring can be shielded, the site of oxidation of pyrimidine heterocycle by P450 oxidase is blocked, and the instability of compound metabolism is reduced. The high-activity compound or prodrug can be combined with neuraminidase inhibitor, PA endonuclease inhibitor or other anti-influenza drugs to provide drugs for preventing or rapidly curing influenza virus infection clinically.
The invention further provides a pharmaceutical composition containing the heterocyclic compound provided by the invention, an isomer thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition further comprises one or more therapeutic agents selected from neuraminidase inhibitors, PA endonuclease inhibitors, or other anti-influenza drugs.
The invention provides application of the heterocyclic compound or an isomer, a pharmaceutically acceptable salt, a hydrate, a solvate, a crystal or a pharmaceutical composition containing the heterocyclic compound in preparation of a medicament for treating or preventing influenza virus.
Preferably, the invention provides the application of the heterocyclic compound or the isomer, the pharmaceutically acceptable salt, the hydrate, the solvate, the crystal or the pharmaceutical composition containing the heterocyclic compound in preparing anti-influenza medicaments such as PB2 inhibitors and the like.
The invention also provides application of the pharmaceutical composition in preparing a medicament for treating or preventing influenza virus infection and a method for treating or preventing diseases of patients infected by the influenza virus by using the pharmaceutical composition.
The pharmaceutical composition according to the invention, wherein the compound of the invention is preferably present in a therapeutically effective amount.
The pharmaceutically acceptable carrier in the pharmaceutical composition may be, for example, pharmaceutically acceptable diluents, excipients, fillers, binders, disintegrants, absorption enhancers, surfactants, lubricants, flavoring agents, sweeteners, etc.
The medicine prepared by taking the compound of the invention as an active ingredient can be various forms such as tablets, powder, capsules, granules, oral liquid, injection preparations and the like. The dosage form of the pharmaceutical composition is preferably tablets, capsules or injections.
The medicaments in various dosage forms can be prepared by the conventional method in the pharmaceutical field.
The invention also provides the use of a compound of the invention in the preparation of a medicament for the prophylaxis or treatment of a viral infectious disease, preferably wherein the viral infectious disease is an influenza virus infection.
In one specific aspect of the present invention, the pharmaceutical composition of the present invention may comprise:
due to the implementation of the technical scheme, compared with the prior art, the invention has the following advantages:
the invention provides a novel heterocyclic compound, which has great advantages compared with the existing neuraminidase inhibitor widely used, and the compounds are shown as a strong influenza A virus inhibitor and effectively inhibit the replication and synthesis of virus RNA. These compounds still have potent protective effects against both severe cases and those with influenza infection for 120 hours, whereas neuraminidase inhibitors are effective only for 48 hours and are not effective in cases with severe influenza infection. The heterocyclic compound has strong PB2 inhibitory activity, excellent pharmacokinetic properties and strong drug forming property.
Further, according to the compound of the present invention, the hydrogen atom adjacent to the nitrogen atom of the pyrimidine ring structure is substituted by methyl, cyclopropyl and the like, compared with other substituents such as thiophene ring and the like, the substituents can block the oxidation of P450 better, reduce the metabolic instability of the compound, and facilitate the improvement of the bioavailability of the drug and the reduction of the dosage of the clinical drug.
Further, based on the structural analysis of the co-crystal, R is on the pyrimidine ring structure2The substituted position is a hydrophobic cavity, the newly generated hydrophobic effect reduces the binding energy of the compound, so that the inhibitory activity of the compound is greatIs improved.
The compound of the invention is used for treating clinical influenza patients or used as stock drugs for preventing large influenza by being used alone or being combined with neuraminidase inhibitors, PA endonuclease inhibitors or other anti-influenza drugs.
Furthermore, the heterocyclic compound provided by the invention is simple in structure and can be prepared at a lower cost.
Detailed Description
Definition of terms
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The term "isomer" refers to isomers resulting from the difference in the arrangement of atoms in a molecule in space. Including cis-trans isomers, enantiomers, and conformers. All stereoisomers are within the scope of the present invention. The compounds of the invention may be individual stereoisomers or mixtures of other isomers, such as racemates, or mixtures of all other stereoisomers.
The term "salt" refers to a pharmaceutically acceptable salt of a compound of the invention with an acid, which may be an organic or inorganic acid, and is specifically selected from: phosphoric acid, sulfuric acid, hydrochloric acid, hydrobromic acid, citric acid, maleic acid, malonic acid, mandelic acid, succinic acid, fumaric acid, acetic acid, lactic acid, nitric acid, sulfonic acid, p-toluenesulfonic acid, malic acid, methanesulfonic acid, or the like.
The term "solvate" refers to a form of a compound of the present invention that forms a solid or liquid complex by coordination with a solvent molecule. Hydrates are a special form of solvates in which coordination occurs with water. Within the scope of the present invention, the solvate is preferably a hydrate.
The term "crystalline" refers to the various solid forms formed by the compounds of the present invention, including crystalline forms, amorphous forms.
The term "hydrocarbyl" refers to a straight, branched, or cyclic, saturated or unsaturated substituent consisting essentially of carbon and hydrogen. Preferably 1 to 20 carbon atoms, more preferably 1 to 12 carbon atoms. The term "alkyl" refers to a straight, branched, saturated hydrocarbon group. Alkyl includes in particular methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, cyclobutyl, n-pentyl, isopentyl, neopentyl, cyclohexyl, n-hexyl, isohexyl, 2, -methylbutyl and 2, 3-dimethylbutyl, 16-alkyl, 18-alkyl. The term "C1-20 alkyl" refers to straight chain, branched chain saturated hydrocarbon radicals containing from 1 to 20 carbon atoms. Substituted alkyl refers to alkyl substituted with a substituent. When the alkyl group is substituted, the substituent may be substituted at any available point of attachment, and the substituent may be mono-or poly-substituted. The substituents are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, deuterium, halogen, thiol, hydroxy, nitro, carboxy, ester, cyano, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, oxo, the substituents usually preceded by alkyl when named.
The term "cycloalkyl" refers to a saturated and/or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon group. A single ring may comprise 3-10 carbon atoms. Non-limiting examples of monocyclocycloalkane groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl and the like. Polycyclic cycloalkyl groups include spiro, fused and bridged cycloalkyl groups. Cycloalkyl includes unsubstituted and substituted. The substituent is selected from one or more substituent groups, including but not limited to the following groups, independently selected from alkyl, cycloalkyl, alkoxy, halogen, carboxyl, ester group, amino, amido, hydroxyl, cyano, nitro, aryl, heteroaryl.
The term "halogen" means fluorine, chlorine, bromine, iodine, preferably fluorine, chlorine, bromine.
The term "haloalkyl" refers to an alkyl group substituted with at least one halogen atom.
The following examples are presented to enable one of ordinary skill in the art to more fully understand the present invention and are not intended to limit the invention in any way. All compounds have the structure1H NMR or MS.
The compound names used in the examples are abbreviated as follows:
DCM: dichloromethane; EtOAc: ethyl acetate; THF, tetrahydrofuran; DME: ethylene glycol dimethyl ether; 1, 4-Dioxane: 1, 4-dioxane; pd2(dba)3: tris (dibenzylideneacetone) dipalladium; xantphos: 4, 5-bis-diphenylphosphino-9, 9-dimethylxanthene; tBuONa: sodium tert-butoxide; TsCl: p-toluenesulfonyl chloride; DIPEA: diisopropylethylamine; pd (dppf) Cl2: [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride; mCPBA: m-chloroperoxybenzoic acid; x-phos: 2-dicyclohexylphosphonium-2, 4, 6-triisopropylbiphenyl.
The preparation methods of compound Int-1 and compound Int-2 in the following examples are as follows.
Preparation of (1S, 2S, 3S, 4R) -3-aminobicyclo [2.2.2]Oct-5-ene-2-carboxylic acid ethyl ester trifluoroacetate salt (Compound No.)
Substance Int-1)
Preparation of compound 2:
maleic anhydride (10g,0.1mol) was dissolved in chloroform (100mL), cooled to 0 ℃ and 1, 3-cyclohexadiene (11.2mL,0.11mol) was added dropwise to the reaction mixture, and after the addition, the temperature was slowly raised to room temperature and the mixture was stirred overnight in the absence of light. The reaction was concentrated, methanol (70mL) was added, heated to 50 ℃, stirred for 10min, ice-cooled to 0 ℃, stirred for 30min, filtered and dried to give compound 2(14g, 71%) as a white solid.1H NMR(400MHz,CDCl3):δ6.31-6.32(m,2H),3.21-3.22(m,2H),3.14-3.16(m，2H),1.60-1.64(m,2H),1.59-1.60(m,2H).13C NMR(100MHz,CDCl3)δ:172.9,133.1,44.6,31.6,22.8.
Preparation of compound 3:
compound 2(24.6g,138.0mmol) and quinine (49.2g,151.6mmol) were suspended in anhydrous toluene (92mL), the reaction was cooled to-16 deg.C, anhydrous ethanol (52.4mL,898.6mmol) was added dropwise, the reaction was allowed to react at-20 deg.C for 20h, filtered, the filter cake was washed with a small amount of cooled toluene and dried at room temperature to give compound 3(57g, 75%) as a white solid.
Preparation of compound 4:
suspending compound 3(5.77g, 10.5mmol) in toluene (29mL), adding 6N hydrochloric acid (3.9mL) under ice bath, heating to room temperature, stirring below 25 ℃ until the solid becomes liquid completely, standing for about 1 hour, separating the organic phase, washing the aqueous phase with toluene (10mLx2), combining the organic phases, adding anhydrous sodium sulfate (6g), stirring in a refrigerator below 5 ℃ for 8-12 hours under sealed conditions, filtering the reaction solution through a funnel filled with anhydrous sodium sulfate, washing a small amount of toluene, cooling the obtained toluene solution to-20 ℃, slowly adding potassium tert-amylate (1.7M, 8mL), strongly stirring, adding dropwise, stirring at-20 ℃ for 30-40 minutes, adding acetic acid (0.3mL), adding 2N hydrochloric acid (8.1mL), stirring at about 5 ℃ for 30 minutes, standing, separating the aqueous phase, washing the organic phase with a buffer solution (2mL x3) (the preparation of the buffer solution is 7.9g of sodium dihydrogen phosphate and 1.3g of phosphorus phosphate and the organic phase is prepared by 7.9g Disodium hydrogen acid and 143mL of purified water), toluene was distilled off to obtain an oily liquid, heptane (2mL) was added, and the mixture was stirred at 40 ℃ for 30 minutes and placed in a 0 ℃ freezer overnight, and the resulting crystals were washed with a small amount of heptane to obtain 1.5g of colorless crystals (64%).
1H NMR(400MHz,CDCl3):δ11.74(brs,1H),6.37(t,J＝7.2Hz,1H),6.22(t,J＝7.2Hz,1H),4.14-4.22(m,2H),3.20(dd,J＝2.4Hz,J＝5.6Hz,1H),3.05-3.07(m,1H),2.95-2.97(m,1H),2.83-2.85(m,1H),1.61-1.67(m,1H),1.45-1.52(m,1H),1.30-1.34(m,1H),1.25(t,J＝7.2Hz,3H),1.09-1.17(m,1H).13C NMR(100MHz,CDCl3):δ180.4,173.7,134.6,132.5,60.9,45.8,45.1,32.5,32.3,24.3,20.2,14.2.
Preparation of compound 5:
triethylamine (5.8mL,41.6mmol) was slowly added to a solution of Compound 4(4.3g,19.1mmol) in toluene (50mL), then warmed to 95 deg.C, DPPA (diphenylphosphoryl azide) (4.1mL,19.0mmol) was added dropwise, reacted at 96 deg.C for 1 hour, t-butanol (3.6mL,38.2mmol) was added, reacted at 96 deg.C overnight, cooled to room temperature, Boc was added2O (4.1g,19.0mmol), stirred overnight, poured into saturated sodium bicarbonate solution, extracted with ethyl acetate, washed with saturated brine, concentrated, and purified by column chromatography to give 1.1g of compound 5.
Preparation of Compound Int-1:
trifluoroacetic acid (5mL) was added dropwise to an ice-cooled solution of compound 5(2g,6.7mmol) in dichloromethane (10mL) over 5 minutes, stirring was continued for 30 minutes while cooling, TLC showed almost complete consumption of starting material, dichloromethane and trifluoroacetic acid were evaporated under reduced pressure, diethyl ether (5mL) was added, stirring was carried out, diethyl ether was evaporated under reduced pressure, and the resulting solid was washed twice with diethyl ether to give a white solid, compound Int-1, 1.5g, 78%.
1H NMR(400MHz,DMSO-d6):δ7.95(brs,3H),6.50(t,J＝7.2Hz,1H),6.17(t,J＝7.2Hz,1H),4.09-4.19(m,2H,3.66(m,1H),2.87-32.89(m,1H),2.80-2.81(m,1H),2.30(m,1H),1.48-1.53(m,1H),1.20-1.35(m,5H),1.02-1.09(m,1H).13C NMR(100MHz,DMSO-d6):δ172.1,136.2,130.4,61.2,51.4,48.8,33.0,32.9,22.7,19.5，14.4.
Preparation of 5-fluoro-3- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1-toluenesulfonyl-
1H-pyrrolo [2,3-b]Pyridine (Compound Int-2)
Preparation of compound 7: n-bromosuccinimide (NBS,5.29g,29.7mmol) was added to a solution of Compound 6(4.50g,33mmol) in dichloromethane (100mL) and reacted at room temperature for 19 hours, after completion of the reaction, a saturated sodium bisulfite solution (200mL) was added, the organic layer was separated, washed with 20% sodium hydroxide solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to give crude 4.62 g.
Preparation of compound 8: compound 7(4.40g, 20.4mmol) was dissolved in 30mL dry DMF and sodium hydride (1.30g,32.6mol) was added and stirred for 30 min. Then p-toluenesulfonyl chloride (5.78g,30.6mmol) was added and reacted for 4 hours. After the reaction, the mixture was poured into an ice-water mixture to precipitate a solid, which was filtered, the filter cake was washed with petroleum ether, and the crude product was recrystallized from ethyl acetate to give 3.10g of Compound 8. Yield: 42.1 percent.
Preparation of compound int-2: compound 8(1.50g,4.05mmol), bis-pinacolato borate (3.089g,12.16mmol), Pd (dppf) Cl2(0.296g,0.41mmol) and potassium acetate (1.193g,12.16mmol) were added to 25mL of 1,4-dioxane, the oxygen was removed from the system by nitrogen bubbling, the mixture was heated under reflux for 19 hours, spun dry, the crude product was dissolved in ethyl acetate (150mL), passed through a silica gel pad, and the product was recrystallized from methyl tert-butyl ether (4.5mL) and petroleum ether (15mL) to give 0.605g of product. Yield: 35.9 percent.
The invention will be further described with reference to specific examples:
example 1: preparation of (2S, 3S) -3- ((5-fluoro-2- (5-fluoro-1H-pyrrolo [2,3-b ] pyridin-3-yl) -6-methylpyrimidin-4-yl) amino) bicyclo [2.2.2] oct-5-ene-2-carboxylic acid (I-1)
Preparation of compound 1 b:
methyl magnesium bromide (27mL,0.027mol,1M tetrahydrofuran solution) was added to a three-necked flask, cooled to 0 deg.C, added with a tetrahydrofuran solution (10mL) of Compound 1a (2.990g,0.018mol), and stirred at 10-15 deg.C for 1 h; cooled to 0 ℃ and triethylamine (2.5mL,0.018mol) and I were added dropwise in that order2(4.960g,0.018mol) in THF (60mL), after addition the temperature was maintained for 1h and then overnight at room temperature. The mixture was washed with sodium hydrogen sulfite solution, extracted with ethyl acetate (150mL) 3 times, and the ethyl acetate layers were combined, washed with water (200mL) and saturated brine (200mL) in this order, dried over anhydrous sodium sulfate and concentrated, and the crude product was purified by silica gel column chromatography (PE/EA ═ 100/5) to give 1.010g of pale yellow oil, which was compound 1 b.
Preparation of compound 1 c:
compound 1b (0.130g,0.718mmol), compound Int-1(0.204g,0.718mmol) and DIPEA (0.401g,2.730mmol) were added sequentially to tetrahydrofuran (30mL) and absolute ethanol (2mL), heated to reflux and stirred for 12 h. After quenching with water, ethyl acetate (30mL) was extracted 2 times, the ethyl acetate layers were combined, washed with saturated brine (30mL), dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure, and purified by silica gel column chromatography (PE/EA ═ 20/1 to 10/1) to obtain 0.115g of a pale yellow oil, which was compound 1 c.
Preparation of compound 1 d:
compound 1c (0.115g,0.338mmol), compound Int-2(0.311g,0.745mmol) and sodium carbonate (0.110g,1.02mmol) were charged into a 100mL single-neck flask, replaced with nitrogen three times, and Pd was added2(dba)3(0.016g,0.016mmol) and X-phos (0.040g,0.085mmol) were purged with nitrogen three times, 2-methyltetrahydrofuran (5mL) and water (1mL) were added, purged with nitrogen three times again, and heated to reflux for 7 h. Cooling to room temperature, and purifying the crude product by direct silica gel column chromatography (PE: EA 15:1) to obtain 0.199g of light yellow solid, namely compound 1 d.
1HNMR(400MHz,CDCl3)δ:8.63(dd,1H,J1＝2.8Hz,J2＝8.4Hz),8.59(s,1H),8.32(d,1H,J＝2.0Hz),8.15(d,2H,J＝8.4Hz),7.31(s,1H),6.61(t,1H,J1＝7.2Hz,J2＝7.6Hz),6.32(t,1H,J1＝6.8Hz,J2＝7.6Hz),4.89-4.80(m,2H),4.32-4.17(m,2H),2.99-2.96(m,1H),2.93-2.90(m,1H),2.41(d,3H,J＝2.8Hz),2.40(s,3H),2.25-2.23(m,1H),1.91-1.85(m,1H),1.73-1.72(m,1H),1.57-1.46(m,1H),1.38-1.33(m,1H),1.26-1.15(m,4H).
Preparation of Compound I-1:
compound 1d (0.190g,0.320mmol) was dissolved in methanol (2mL) and dioxane (2mL), and an aqueous solution of lithium hydroxide (0.055g,1.280mmol,2mL water) was added and after the addition was complete, the reaction was heated to reflux for 3 h. Concentrated to dryness under reduced pressure, dissolved in ethyl acetate (20mL) and water (20mL), adjusted to pH 6 with 1N hydrochloric acid, extracted 3 times with ethyl acetate (20mL), combined with ethyl acetate layers, washed with saturated brine, dried over sodium sulfate and concentrated under reduced pressure, and subjected to crude silica gel column chromatography (PE/EA 5:1) to obtain 0.065g of a pale yellow solid, i.e., compound I-1.
1HNMR(400MHz,CDCl3)δ:11.68(s,1H),8.71(dd,1H,J1＝2.4Hz,J2＝8.8Hz),8.58(d,1H,J＝2.0Hz),8.01(t,1H,J1＝2.0Hz,J2＝7.2Hz),6.71(t,1H,J1＝7.2Hz,J2＝7.2Hz),6.44(t,1H,J1＝6.4Hz,J2＝8.0Hz),5.31(m,1H),4.90(m,1H),3.15-3.13(m,1H),2.85(m,1H),2.42(d,1H,J＝4.8Hz),2.35(m,1H),1.91-1.76(m,2H),1.50-1.42(m,1H),1.24-1.18(m,4H).
LC/MS m/z：412.1(M+H).
Example 2: preparation of (2S, 3S) -3- (6-cyclopropyl-5-fluoro-2- (5-fluoro-1H-pyrrolo [2,3-b ] pyridin-3-yl) -pyrimidin-4-yl) amino) bicyclo [2.2.2] oct-5-ene-2-carboxylic acid (I-7)
Preparation of compound 7 b:
adding cyclopropyl magnesium bromide (27mL,27.000mmol,1M tetrahydrofuran solution) into a three-neck flask, cooling to 0 deg.C, adding tetrahydrofuran solution (20mL) of compound 1a (2.980g,17.850mmol), stirring at 10-15 deg.C for 1h, cooling to 0 deg.C, sequentially adding triethylamine (2.5mL,17.850mmol) and I2(4.960g,17.850mmol) in THF (60mL) was stirred at this temperature for 1h after the addition was complete and then at room temperature overnight. The mixture was washed with sodium hydrogen sulfite solution, extracted with ethyl acetate (150mL) 3 times, and the ethyl acetate layers were combined, washed with saturated brine (200mL), dried over anhydrous sodium sulfate, concentrated to dryness under reduced pressure, and purified by silica gel column chromatography (PE/EA ═ 100/5) to give 2.310g of a pale yellow solid, i.e., compound 7 b.
Preparation of compound 7 c:
compound 7b (0.082g,0.396mmol), Int-1(0.115g,0.396mmol) and DIPEA (0.194g,1.505mmol) were added to tetrahydrofuran (15mL) and absolute ethanol (1mL) in that order, heated to reflux and stirred for 6h, and the TLC detection reaction was complete. And adding one more batch according to the feeding amount and operation, combining the two batches of reaction liquid after the second batch of reaction is finished, adding water for quenching, extracting for 2 times by using ethyl acetate (30mL), combining ethyl acetate layers, washing by using saturated saline solution (30mL), drying by using anhydrous sodium sulfate, concentrating under reduced pressure to dryness, and purifying by using silica gel column chromatography (PE/EA is 100/5) to obtain 0.154g of light yellow solid, namely the compound 7 c.
Preparation of compound 7 d:
compound 7c (0.154g,0.421mmol), int-2(0.386g,0.926mmol) and sodium carbonate (0.134g,1.260mmol) were charged into a 100mL single-necked flask, and Pd was added after three-time replacement with nitrogen2(dba)3(0.019g,0.021mmol) and X-phos (0.050g,0.105mmol), three times with nitrogen substitution; 2-methyltetrahydrofuran (5mL) and water (1mL) were added, the mixture was again replaced with nitrogen three times, and the mixture was heated to reflux for 7 h. Cooling to room temperature, directly mixing the crude product with silica gel column chromatography (PE: EA is 10:1), and purifying to obtain solid 0.250g, i.e. compoundAnd (7 d) a compound.
1HNMR(400MHz,CDCl3)δ:8.54(s,1H),8.46(dd,1H,J1＝2.8Hz,J2＝9.2Hz),8.31(d,1H,J＝2.0Hz),8.14(d,2H,J＝8.4Hz),7.32(s,1H),6.59(t,1H,J1＝8.0Hz,J2＝7.2Hz),6.33(t,1H,J1＝6.8Hz,J2＝7.6Hz),4.87-4.78(m,2H),4.37-4.14(m,2H),2.98-2.95(m,1H),2.92-2.90(m,1H),2.39(s,3H),2.26-2.22(m,2H),1.92-1.86(m,1H),1.72-1.66(m,1H),1.46-1.39(m,1H),1.30-1.26(m,1H),1.24-1.18(m,5H),1.08-1.05(m,2H).
Preparation of Compound I-7:
compound 7d (0.240g,0.387mmol) was dissolved in methanol (2mL) and dioxane (2mL), and an aqueous solution of lithium hydroxide (0.068g,1.548mmol,2mL water) was added and after the addition was complete, the reaction was heated to reflux for 3 h. Concentrated to dryness under reduced pressure, dissolved in ethyl acetate (20mL) and water (20mL), adjusted to pH 6 with 1N hydrochloric acid, extracted 3 times with ethyl acetate (20mL), combined with ethyl acetate layers, washed with saturated brine, dried over sodium sulfate, concentrated to dryness under reduced pressure, and purified by crude thin layer chromatography (DCM: MeOH ═ 15:1) to give 0.067g of a pale yellow solid, i.e., compound I-7.
1HNMR(400MHz,CDCl3)δ:11.68(s,1H),8.58(d,1H,J＝2.4Hz),8.46(dd,1H,J1＝2.8Hz,J2＝9.2Hz),7.99(t,1H,J＝2.4Hz),6.69(t,1H,J1＝4.0Hz,J2＝7.2Hz),6.44(t,1H,J1＝6.4Hz,J2＝7.2Hz),5.29(d,1H,J＝9.6Hz),4.87(d,1H,J＝9.2Hz),3.15-3.12(m,1H),2.87-2.85(m,1H),2.35-2.34(m,1H),2.28-2.25(m,1H),1.88-1.76(m,2H),1.50-1.43(m,1H),1.32-1.22(m,4H),1.08-1.06(m,2H).
LC/MS m/z：438.0(M+H).
Example 3: in vitro bioactivity and cytotoxicity studies
Test compounds: compound I-1 of the present invention, Compound I-7 of the present invention, and control compound VX-787 (Pimodivir). Test methods for in vitro bioactivity studies: MDCK cells were seeded into 384-well cell culture plates at a density of 2,000 cells per well, and then placed in a 5% CO2 incubator at 37 ℃ overnight. The next day the compounds were diluted and added to the wells individually (3 fold dilution, 8 concentration points tested), and influenza A/PR/8/34(H1N1) strain was added to the cell culture wells at 2 TCID90 per well in culture mediumThe final concentration of DMSO was 0.5%. The cell plates were incubated at 37 ℃ with 5% CO2Culturing in an incubator for 5 days. After 5 days of culture, cell viability was measured using CCK8 cell viability assay kit. Nonlinear fitting analysis is carried out on the inhibition rate and cytotoxicity of the compound by using GraphPadprism software on the raw data to obtain EC50Values (see table 1 for results).
Study methods for cytotoxicity study: the cytotoxicity test and the antiviral activity test of the compound are carried out in parallel, and other test conditions are consistent with the antiviral activity test except that no virus is added. After 5 days of culture, cell viability was measured using CCK8 cell viability assay kit. The raw data were used for compound cytotoxicity (CC50) calculations (results see table 1).
TABLE 1 inhibitory Activity and toxicity of Compounds against influenza A/PR/8/34(H1N1)
And (4) conclusion: compounds I-1 and I-7 have excellent activity, EC, for inhibiting H1N150Less than 1nM and has very low cytotoxicity.
The other compounds of the present invention have substantially the same structures as compounds I-1 and I-7, and they are expected to have excellent activities comparable to compounds I-1 and I-7.
In addition, compared with the existing PB2 inhibitor, the compound disclosed by the invention has the advantages of simple structure, good solubility, high bioavailability, stable metabolism and the like.
The above description of the embodiments is only intended to facilitate the understanding of the method of the invention and its core idea. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention.
Claims (10)
1. Heterocyclic compounds of general formula (I), stereoisomers, pharmaceutically acceptable salts, solvates or crystals thereof,
wherein R is1Selected from F or Cl;
R2the compound is selected from C1-C8 alkyl, C3-C6 cycloalkyl, substituted C1-C8 alkyl and substituted C3-C6 cycloalkyl, wherein the substituent of the substituted alkyl and the substituted cycloalkyl is one or more independently selected from fluorine, chlorine, C1-C8 alkyl and C1-C8 alkoxy;
R3selected from hydrogen, hydrocarbyl carbonyl oxygen of C1-C8, hydrocarbyl of C1-C4, hydrocarbyl oxygen carbonyl oxygen of C1-C8, hydrocarbyl-of C1-C4; z is selected from N or CH.
2. The heterocyclic compound according to claim 1, which is a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a crystal thereof, characterized in that: in the formula (I), R2Is selected from C1-C8 alkyl, C3-C6 cycloalkyl, substituted C1-C8 alkyl and substituted C3-C6 cycloalkyl, wherein the substituent groups in the substituted alkyl and the substituted cycloalkyl are independently one or more selected from fluorine, chlorine, C1-C8 alkyl and C1-C8 alkoxy.
3. The heterocyclic compound according to claim 2, which is a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a crystal thereof, characterized in that: in the formula (I), R2Is selected from C1-C6 alkyl, C3-C6 cycloalkyl, substituted C1-C6 alkyl and substituted C3-C6 cycloalkyl, wherein the substituent groups in the substituted alkyl and the substituted cycloalkyl are independently one or more selected from fluorine, chlorine, C1-C3 alkyl and C1-C3 alkoxy.
4. The heterocyclic compound represented by the general formula (I), a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a crystal thereof according to claim 3, characterized in that: in the formula (I), R2Selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, fluoromethyl, fluoroethylFluoro-n-propyl, fluoro-isopropyl, fluoro-cyclopropyl, fluoro-cyclobutyl, fluoro-cyclopentyl, fluoro-cyclohexyl, chloromethyl, chloroethyl, chloro-n-propyl, chloro-isopropyl, chloro-cyclopropyl, chloro-cyclobutyl, chloro-cyclopentyl, chloro-cyclohexyl, methoxy-substituted methyl, methoxy-substituted ethyl, methoxy-substituted cyclopropyl, methoxy-substituted cyclobutyl, ethoxy-substituted methyl, ethoxy-substituted ethyl, ethoxy-substituted cyclopropyl, ethoxy-substituted cyclobutyl.
5. The heterocyclic compound according to claim 1, which is a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a crystal thereof, characterized in that: in the formula (I), R3Selected from hydrogen, alkyl carbonyl oxygen of C1-C8, alkyl of C1-C4 and alkoxy carbonyl oxygen of C1-C8, and alkyl of C1-C4.
6. The heterocyclic compound according to claim 5, which is a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a crystal thereof, characterized in that: in the formula (I), R3Selected from hydrogen, alkyl carbonyl oxygen of C1-C4, alkyl of C1-C2 and alkoxy carbonyl oxygen of C1-C4, and alkyl of C1-C2.
7. The heterocyclic compound represented by the general formula (I), a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a crystal thereof according to any one of claims 1 to 6, characterized in that: r3Selected from the group consisting of hydrogen, methylcarbonyloxymethyl-, methylcarbonyloxy 1-ethyl-, ethylcarbonyloxymethyl-, isopropylcarbonyloxymethyl-, tert-butylcarbonyloxymethyl-, methoxycarbonyloxymethyl-, methoxycarbonyloxy 1-ethyl-, ethoxycarbonyloxymethyl-, isopropoxycarbonyloxymethyl-, n-butyloxycarbonyloxymethyl-, isopropyloxycarbonyloxy 1-ethyl-.
8. The heterocyclic compound represented by the general formula (I), a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof according to claim 1, wherein the compound is represented by the formula (I-1), the formula (I-2), the formula (I-3), the formula (I-4), the formula (I-5), the formula (I-6), the formula (I-7), the formula (I-8), the formula (I-9), the formula (I-10), the formula (I-11), the formula (I-12), the formula (I-13), the formula (I-14), the formula (I-15), the formula (I-16), the formula (I-17), the formula (I-18), the formula (I-19), the formula (I-20), the formula (I-21), the formula (I-22), the formula (I-23), A compound represented by the formula (I-24), the formula (I-25), the formula (I-26), the formula (I-27), the formula (I-28), the formula (I-29), the formula (I-30), the formula (I-31), the formula (I-32), the formula (I-33), the formula (I-34), the formula (I-35), the formula (I-36), the formula (I-37), the formula (I-38), the formula (I-39) or the formula (I-40),
9. a pharmaceutical composition comprising a heterocyclic compound of formula (I), a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof according to any of claims 1 to 8, which is an antiviral pharmaceutical composition optionally further comprising one or more therapeutic agents selected from the group consisting of: neuraminidase inhibitors, nucleoside drugs, PB2 inhibitors, PB1 inhibitors, M2 inhibitors or other anti-influenza drugs.
10. Use of the heterocyclic compound of formula (I), a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof, or the pharmaceutical composition of claim 9 according to any one of claims 1 to 8 for the preparation of a medicament for the prevention and/or treatment of a viral infectious disease, preferably an infectious disease caused by influenza a or influenza B.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810605064.2A CN110590768B (en) | 2018-06-13 | 2018-06-13 | Heterocyclic compounds, compositions thereof and their use as anti-influenza virus agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810605064.2A CN110590768B (en) | 2018-06-13 | 2018-06-13 | Heterocyclic compounds, compositions thereof and their use as anti-influenza virus agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110590768A true CN110590768A (en) | 2019-12-20 |
| CN110590768B CN110590768B (en) | 2021-02-26 |
Family
ID=68848937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810605064.2A Active CN110590768B (en) | 2018-06-13 | 2018-06-13 | Heterocyclic compounds, compositions thereof and their use as anti-influenza virus agents |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110590768B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458408A (en) * | 2009-06-17 | 2012-05-16 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
| CN103492381A (en) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
| WO2017097234A1 (en) * | 2015-12-09 | 2017-06-15 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| WO2017133667A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof |
| WO2018041263A1 (en) * | 2016-09-05 | 2018-03-08 | 广东众生药业股份有限公司 | Anti-influenza virus pyrimidine derivative |
-
2018
- 2018-06-13 CN CN201810605064.2A patent/CN110590768B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458408A (en) * | 2009-06-17 | 2012-05-16 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
| CN103492381A (en) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
| WO2017097234A1 (en) * | 2015-12-09 | 2017-06-15 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| WO2017133667A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof |
| WO2018041263A1 (en) * | 2016-09-05 | 2018-03-08 | 广东众生药业股份有限公司 | Anti-influenza virus pyrimidine derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110590768B (en) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022143473A1 (en) | Nucleoside compound and use thereof | |
| CN110041327B (en) | Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament | |
| EP3325477B1 (en) | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection | |
| CN110317211B (en) | Substituted polycyclic pyridone compound and prodrug thereof | |
| ES2763535T3 (en) | Flu virus replication inhibitors | |
| CN108290869B (en) | Heterocyclic indoles for use in influenza virus infection | |
| KR20150039832A (en) | Dihydroxypyrimidine Carbonic Acid Derivatives and Their Use in the Treatment, Amelioration or Prevention of a Viral Disease | |
| EP2858984A1 (en) | Inhibitors of influenza viruses replication | |
| CA3059135A1 (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| KR20190056380A (en) | Anti-influenza virus pyrimidine derivative | |
| KR20160052683A (en) | Pyridazinone compounds and uses thereof | |
| WO2017028798A1 (en) | Pyridazinone compound, preparation method, pharmaceutical composition and use thereof | |
| TW201726678A (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| AU2012367780A1 (en) | Derivatives of aza adamantane and uses thereof | |
| US8759544B2 (en) | Synthesis of an antiviral compound | |
| KR101902567B1 (en) | Fluorosubstituted (3R,4R,5S)-5-guanidino-4-acetamido-3-(pentan-3-yloxy)cyclohexene-1- carboxylic acids, their esters and use thereof | |
| CN112771048B (en) | Inhibitors of influenza virus replication and intermediates and uses thereof | |
| CN110590768B (en) | Heterocyclic compounds, compositions thereof and their use as anti-influenza virus agents | |
| CN115135646B (en) | Substituted polycyclic compounds, pharmaceutical compositions and uses thereof | |
| CN104177327A (en) | Preparation method of 6-amino-2-thiospiro[3,3]heptane hydrochloride | |
| RU2720305C1 (en) | Substituted 3,4,12,12a-tetrahydro-1h-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, methods for production and use thereof | |
| WO2021249522A1 (en) | Pyridone-containing fused ring derivative inhibitor, preparation method therefor, and use thereof | |
| CN113527296A (en) | Influenza virus inhibitor | |
| CN109384783A (en) | Novel heterocyclic compounds and its medical usage as resisiting influenza virus inhibitor | |
| CN112300147B (en) | Pyridine compound, preparation method and application thereof, and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231007 Address after: Unit 301, Building C11, Bionano Park, No. 218 Xinghu Street, Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee after: Suzhou Yuanzhi Pharmaceutical Technology Co.,Ltd. Address before: 3 / F, C11 / F, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province Patentee before: GINKGO PHARMA Co.,Ltd. |
|
| TR01 | Transfer of patent right |